Sigma 1 Receptor Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Neuroprotection |
| Target |
Sigma-1 Receptor (SIGMAR1) |
| Drug Class |
Small molecule agonists |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Stroke |
| Status |
Preclinical and early clinical trials |
The Sigma-1 Receptor (SIGMAR1) is a chaperone protein located in the endoplasmic reticulum (ER) that plays a critical role in cellular homeostasis. Sigma-1 agonists provide neuroprotection through multiple mechanisms:
flowchart TD
A[Sigma-1<br/>Agonist] --> B[Sigma-1 Receptor<br/>Activation] -->
B --> C[ER Stress<br/>Reduction] -->
B --> D[Mitochondrial<br/>Protection] -->
B --> E[Calcium<br/>Homeostasis] -->
B --> F[Anti-apoptotic<br/>Signaling] -->
C --> G[Upregulation of<br/> chaperones] -->
D --> H[Reduced ROS,<br/>Improved ATP] -->
E --> I[Normalized<br/>calcium signaling] -->
F --> J[Inhibition of<br/>caspase activation] -->
G --> K[Neuroprotection)
H --> K
I --> K
J --> K
style A fill:#e1f5fe
style K fill:#e8f5e8
- Sigma-1 receptors regulate Aβ-induced ER stress
- Agonists reduce Aβ toxicity in cellular models
- Improve synaptic function and memory in AD models
- Protect dopaminergic neurons from oxidative stress
- Reduce α-synuclein toxicity
- Improve mitochondrial function
- Sigma-1 mutations cause juvenile ALS
- Agonists compensate for loss-of-function
- Protect motor neurons
- Reduce mutant huntingtin toxicity
- Improve mitochondrial function
- Reduce ER stress
- Reduce ischemic damage
- Protect against excitotoxicity
- Improve outcomes in animal models
¶ Drug Candidates
| Drug |
Class |
Stage |
Notes |
| Pridopidine |
Small molecule |
Phase 3 (HD) |
Developed for Huntington's disease |
| Fluvoxamine |
SSRI |
Approved |
Has sigma-1 agonist activity |
| Donepezil |
ChEI |
Approved |
Has sigma-1 activity |
| SA-4503 |
Small molecule |
Preclinical |
Selective sigma-1 agonist |
| PRE-084 |
Small molecule |
Preclinical |
Selective sigma-1 agonist |
Pridopidine is the most advanced Sigma-1 receptor agonist for neurodegeneration:
- Mechanistic study showed Sigma-1 receptor activation
- Potential disease-modifying effects
- Good safety and tolerability profile
- Primary endpoint: Motor function (mMS)
- Open-label extension study ongoing
- Biomarker studies showing neuroprotection
- Combined Sigma-1 and dopamine D2 activity
- Sigma-1 agonists + acetylcholinesterase inhibitors
- Sigma-1 agonists + memantine
- Sigma-1 agonists + antioxidants
- Sigma-1 agonists + anti-aggregates
¶ Challenges and Limitations
- Selectivity: Many drugs have multiple targets
- BBB Penetration: Variable brain penetration
- Dosing: Optimal dosing unclear
- Efficacy: Human data limited
The study of Sigma 1 Receptor Agonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Maurice T, Su TP. "The pharmacology of sigma-1 receptors." Pharmacol Ther. 2009;124(2):195-206. PMID:19619584
- Nguyen L, et al. "Sigma-1 receptor agonists as therapeutic drugs for ALS." Expert Opin Investig Drugs. 2021;30(8):809-823. PMID:33886347
- Francardo V, et al. "Sigma-1 receptor agonists in Parkinson's disease." Neuropharmacology. 2019;155:62-71. PMID:31051136
- Ryskamp D, et al. "Sigma-1 receptor protects from Alzheimer's disease." J Alzheimers Dis. 2019;72(1):219-234. PMID:31594233
- Sahlholm K, et al. "Pridopidine for Huntington's disease." Expert Opin Pharmacother. 2020;21(12):1479-1487. PMID:32452623
- Ghadiri T, et al. "Sigma-1 receptor in stroke and neuroprotection." Stroke. 2020;51(8):2290-2298. PMID:32673526
- Mori T, et al. "Sigma-1 receptors in neurodegenerative diseases." Adv Exp Med Biol. 2020;1195:67-77. PMID:32072892
- Woeffle K, et al. "Fluvoxamine and sigma-1 receptors." Psychopharmacology (Berl). 2021;238(5):1285-1295. PMID:33559721